Massimo Cristofanilli, MD, on Breast Cancer: Updated Analysis on Palbociclib Plus Fulvestrant

June 07, 2021 By The ASCO Post Staff

Massimo Cristofanilli, MD, of the Feinberg School of Medicine at Northwestern University, discusses updated overall survival data from the phase III PALOMA-3 trial of palbociclib plus fulvestrant in women with hormone receptor–positive, HER2-negative advanced breast cancer (Abstract 1000).

Related Content